Which has preferable valuation & earnings, SVRA or FBRX?

Savara is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Forte Biosciences N/A N/A -$69.38M -$4.64 N/A

Is SVRA or FBRX more profitable?

Savara's return on equity of -87.19% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Forte Biosciences N/A -106.17% -85.50%

Which has stronger earnings and valuation, FBRX or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.64 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A

Is FBRX or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -38.92% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% Corvus Pharmaceuticals N/A -38.92% -35.75%

Forte Biosciences (FBRX) Competitors

$15.67 -0.85 (-5.15%)

Closing price 04:00 PM Eastern

Extended Trading

$15.74 +0.06 (+0.41%)

As of 07:55 PM Eastern

Compare

FBRX vs. CRON, SVRA, XERS, CVAC, and CRVS

Should you buy Forte Biosciences stock or one of its competitors? MarketBeat compares Forte Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Forte Biosciences include Cronos Group (CRON), Savara (SVRA), Xeris Biopharma (XERS), CureVac (CVAC), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

How does Forte Biosciences compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Forte Biosciences has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.14%	-1.26%	-1.20%
Forte Biosciences	N/A	-106.17%	-85.50%

In the previous week, Cronos Group had 3 more articles in the media than Forte Biosciences. MarketBeat recorded 3 mentions for Cronos Group and 0 mentions for Forte Biosciences. Cronos Group's average media sentiment score of 0.07 beat Forte Biosciences' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media.

Company	Overall Sentiment
Cronos Group	Neutral
Forte Biosciences	Neutral

Cronos Group has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	7.05	-$9.45M	$0.01	277.00
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cronos Group has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, suggesting that its stock price is 187% more volatile than the broader market.

Cronos Group currently has a consensus price target of $2.30, suggesting a potential downside of 16.97%. Forte Biosciences has a consensus price target of $67.00, suggesting a potential upside of 327.57%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cronos Group beats Forte Biosciences on 9 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to Savara?

Savara (NASDAQ:SVRA) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Savara presently has a consensus price target of $10.14, suggesting a potential upside of 100.45%. Forte Biosciences has a consensus price target of $67.00, suggesting a potential upside of 327.57%. Given Forte Biosciences' higher probable upside, analysts plainly believe Forte Biosciences is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

87.9% of Savara shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Savara has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, indicating that its stock price is 187% more volatile than the broader market.

Savara's return on equity of -87.19% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Forte Biosciences	N/A	-106.17%	-85.50%

In the previous week, Savara had 3 more articles in the media than Forte Biosciences. MarketBeat recorded 3 mentions for Savara and 0 mentions for Forte Biosciences. Savara's average media sentiment score of 0.52 beat Forte Biosciences' score of 0.00 indicating that Savara is being referred to more favorably in the media.

Company	Overall Sentiment
Savara	Positive
Forte Biosciences	Neutral

Savara is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Summary

Savara beats Forte Biosciences on 10 of the 14 factors compared between the two stocks.

How does Forte Biosciences compare to Xeris Biopharma?

Forte Biosciences (NASDAQ:FBRX) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Xeris Biopharma had 9 more articles in the media than Forte Biosciences. MarketBeat recorded 9 mentions for Xeris Biopharma and 0 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.00 beat Xeris Biopharma's score of -0.62 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Neutral
Xeris Biopharma	Negative

Xeris Biopharma has a net margin of 3.81% compared to Forte Biosciences' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Xeris Biopharma	3.81%	735.00%	3.24%

Xeris Biopharma has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Xeris Biopharma	$291.85M	3.69	$550K	$0.06	104.00

Forte Biosciences has a beta of 2.87, meaning that its share price is 187% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Forte Biosciences currently has a consensus price target of $67.00, indicating a potential upside of 327.57%. Xeris Biopharma has a consensus price target of $10.80, indicating a potential upside of 73.08%. Given Forte Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Forte Biosciences is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Xeris Biopharma beats Forte Biosciences on 9 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to CureVac?

Forte Biosciences (NASDAQ:FBRX) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Forte Biosciences has a beta of 2.87, indicating that its stock price is 187% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Forte Biosciences currently has a consensus price target of $67.00, suggesting a potential upside of 327.57%. CureVac has a consensus price target of $5.25, suggesting a potential upside of 12.66%. Given Forte Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Forte Biosciences is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Forte Biosciences' average media sentiment score of 0.00 equaled CureVac'saverage media sentiment score.

Company	Overall Sentiment
Forte Biosciences	Neutral
CureVac	Neutral

CureVac has a net margin of 199.92% compared to Forte Biosciences' net margin of 0.00%. CureVac's return on equity of -23.03% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
CureVac	199.92%	-23.03%	-19.09%

CureVac has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Summary

CureVac beats Forte Biosciences on 7 of the 13 factors compared between the two stocks.

How does Forte Biosciences compare to Corvus Pharmaceuticals?

Forte Biosciences (NASDAQ:FBRX) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Corvus Pharmaceuticals had 3 more articles in the media than Forte Biosciences. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 0 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.00 equaled Corvus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Forte Biosciences	Neutral
Corvus Pharmaceuticals	Neutral

Forte Biosciences has a beta of 2.87, meaning that its stock price is 187% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Corvus Pharmaceuticals' return on equity of -38.92% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Forte Biosciences currently has a consensus target price of $67.00, indicating a potential upside of 327.57%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 198.95%. Given Forte Biosciences' higher probable upside, research analysts clearly believe Forte Biosciences is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Corvus Pharmaceuticals beats Forte Biosciences on 8 of the 12 factors compared between the two stocks.

Get Forte Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBRX vs. The Competition

Export

Metric	Forte Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$229.39M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-3.38	18.61	23.92	23.74
Price / Sales	N/A	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	3.33	8.04	10.28	6.78
Net Income	-$69.38M	$23.89M	$3.57B	$337.51M
7 Day Performance	-18.56%	-5.97%	-1.43%	-2.72%
1 Month Performance	-34.76%	2.78%	3.27%	1.87%
1 Year Performance	38.43%	36.26%	23.37%	26.60%

Forte Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBRX Forte Biosciences	1.3989 of 5 stars	$15.67 -5.1%	$67.00 +327.6%	+45.9%	$229.39M	N/A	N/A	5
CRON Cronos Group	1.4374 of 5 stars	$2.74 -3.0%	$2.30 -15.9%	+38.4%	$1.07B	$159.54M	277.88	450	Positive News
SVRA Savara	2.2044 of 5 stars	$5.26 +2.0%	$10.14 +93.0%	+108.6%	$1.07B	N/A	N/A	20
XERS Xeris Biopharma	3.2304 of 5 stars	$6.00 -1.2%	$10.80 +80.2%	+34.9%	$1.06B	$314.85M	99.50	290	Insider Trade
CVAC CureVac	N/A	$4.66 flat	$5.25 +12.7%	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBRX) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forte Biosciences (FBRX) Competitors

FBRX vs. CRON, SVRA, XERS, CVAC, and CRVS

How does Forte Biosciences compare to Cronos Group?

Summary

How does Forte Biosciences compare to Savara?

Summary

How does Forte Biosciences compare to Xeris Biopharma?

Summary

How does Forte Biosciences compare to CureVac?

Summary

How does Forte Biosciences compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forte Biosciences (FBRX) Competitors

FBRX vs. CRON, SVRA, XERS, CVAC, and CRVS

How does Forte Biosciences compare to Cronos Group?

Is CRON or FBRX more profitable?

Does the media favor CRON or FBRX?

Which has preferable earnings and valuation, CRON or FBRX?

Do institutionals & insiders have more ownership in CRON or FBRX?

Which has more volatility & risk, CRON or FBRX?

Do analysts recommend CRON or FBRX?

Summary

How does Forte Biosciences compare to Savara?

Do analysts recommend SVRA or FBRX?

Do insiders and institutionals hold more shares of SVRA or FBRX?

Which has more risk & volatility, SVRA or FBRX?

Is SVRA or FBRX more profitable?

Does the media prefer SVRA or FBRX?

Which has preferable valuation & earnings, SVRA or FBRX?

Summary

How does Forte Biosciences compare to Xeris Biopharma?

Does the media refer more to FBRX or XERS?

Is FBRX or XERS more profitable?

Which has higher valuation and earnings, FBRX or XERS?

Which has more volatility & risk, FBRX or XERS?

Do analysts recommend FBRX or XERS?

Do institutionals & insiders believe in FBRX or XERS?

Summary

How does Forte Biosciences compare to CureVac?

Which has more risk & volatility, FBRX or CVAC?

Do analysts rate FBRX or CVAC?

Do institutionals and insiders believe in FBRX or CVAC?

Does the media favor FBRX or CVAC?

Is FBRX or CVAC more profitable?

Which has higher earnings and valuation, FBRX or CVAC?

Summary

How does Forte Biosciences compare to Corvus Pharmaceuticals?

Does the media refer more to FBRX or CRVS?

Which has more risk & volatility, FBRX or CRVS?

Is FBRX or CRVS more profitable?

Which has stronger earnings and valuation, FBRX or CRVS?

Do insiders and institutionals believe in FBRX or CRVS?

Do analysts recommend FBRX or CRVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools